Clinical trial
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled…
NCT00121641 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00121641 |
|---|---|
| Title | Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Saxagliptin, Placebo matching Saxagliptin, Metformin, Placebo matching Metformin |
| Enrollment | 1,035 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2006 |
| Completion | Feb 1, 2010 |
| First posted | Jul 21, 2005 |
| Last update posted | Apr 3, 2015 |
| Countries | Australia, Canada, Mexico, Puerto Rico, Taiwan, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: